Avutometinib and Defactinib in Diffuse Gastric Cancer

Part of paid clinical trials in New York, New York.

Sponsor
Ryan H. Moy, MD, PhD
Study ID
NCT06487221
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine if the combination study treatment with avutometinib and defactinib will prolong life in participants, is effective in decreasing the size of the tumor(s), and if it is safe in subjects with diffuse-type stomach cancer.

Key Dates

Start date
Oct 28, 2024
Status verified
Oct 2025
Primary completion
Nov 30, 2028
Completion
May 30, 2029

Study Design

Enrollment
27 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Avutometinib & Defactinib
    Avutometinib: Study participants will receive Avutometinib 3.2mg orally two times per week for three weeks in a row followed by one week of rest Defactinib: Study participants will receive Defactinib 200mg twice daily for three weeks in a row followed by one week of rest

Primary Outcome Measure

Progression-free survival (PFS) Rate [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Columbia University Irving Medical CenterNew YorkNew York10032
Research Nurse Navigator
[email protected]
212-342-5162
Ryan Moy, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

By condition
Gastric cancer
By specialty
OncologyGI oncology
By research site
Columbia University Irving Medical Center· New York, NY

Related Studies